Eiermann T H, Fakler J, Goldmann S F
Department of Transfusion Medicine, University of Ulm, Germany.
Bone Marrow Transplant. 1992 Mar;9(3):157-60.
Bone marrow transplantation from unrelated donors is being used increasingly for the treatment of patients with leukaemia and other disorders of lymphohaemopoiesis. Selection of histocompatible unrelated bone marrow donors currently relies on serological HLA identity and negative mixed lymphocyte cultures (MLC) between potential donor-recipient pairs. Since serological HLA-DP typing is not feasible, we used the HLA-DPB1 oligonucleotide typing method to test whether the current selection procedure can also guarantee identity for HLA-DP. In 40 consecutive patients, one-third (62/193) of the serologically HLA-A, -B, -C, -DR and -DQ identical donors were judged as MLC negative (relative response below 5%) with the presumptive recipient. HLA-DPB1 oligonucleotide typing of the MLC negative donors revealed that only one-third of these (20/62) were also identical for DP. In the majority of the pairs, we found a DPB1 disparity. A difference in the graft-versus-host direction was seen in 25/62 cases in the host-versus-graft direction in 28/62 cases and in both directions in 29/62 cases. These data indicate that, in spite of the strict MLC criteria used, the current procedure did not guarantee complete MHC class II identity. Therefore oligotyping for DPB1 can improve matching for DP and should be introduced for typing of volunteers. We suspect that DP differences may contribute to the higher incidence of graft-versus-host disease or graft rejection in unrelated donor transplants.
来自无关供者的骨髓移植正越来越多地用于治疗白血病和其他淋巴造血系统疾病患者。目前,选择组织相容性无关骨髓供者依赖于血清学 HLA 配型相同以及潜在供受者对之间混合淋巴细胞培养(MLC)阴性。由于血清学 HLA-DP 分型不可行,我们采用 HLA-DPB1 寡核苷酸分型方法来检测当前的选择程序是否也能保证 HLA-DP 的一致性。在连续的 40 例患者中,三分之一(62/193)血清学 HLA-A、-B、-C、-DR 和 -DQ 相同的供者被判定与推定受者的 MLC 为阴性(相对反应低于 5%)。对 MLC 阴性供者进行 HLA-DPB1 寡核苷酸分型显示,其中只有三分之一(20/62)的 DP 也相同。在大多数配对中,我们发现了 DPB1 差异。在 62 例中,25 例在移植物抗宿主方向存在差异,28 例在宿主抗移植物方向存在差异,29 例在两个方向均存在差异。这些数据表明,尽管使用了严格的 MLC 标准,但当前程序并不能保证 MHC Ⅱ类完全匹配。因此,DPB1 寡核苷酸分型可以改善 DP 匹配,应引入用于志愿者分型。我们怀疑 DP 差异可能导致无关供者移植中移植物抗宿主病或移植物排斥发生率较高。